Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Acadia Healthcare Company, Inc.ACHC · Entity 4312 | Director | March 07, 2019 | March 08, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Acadia Healthcare Company, Inc.
Report date March 07, 2019 · Filed March 08, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 266,388 |
Reported balance
After 2019-03-07 transaction · row 1
1 source rowRow 1 · 2019-03-07 · Exercise / conversion · Acquired 18,315 · Balance 266,388 |
| Employee Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.96 · Expires 2019-03-16 | Direct | 0 |
Reported balance
After 2019-03-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-03-07 · Exercise / conversion · Disposed 18,315 · Balance 0 |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 267,649 |
Reported balance
Holding disclosure · report date 2019-03-07 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 267,649 F1: Mr. Jacobs expressly disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interest therein. F2: By the Jeremy Brent Jacobs GST Non-Exempt u/a/d 04/26/2011 and Scott Douglas Jacobs GST Non-Exempt Trust u/a/d 04/26/2011. |
Filing footnotes · ownership attribution and instrument terms
F1: Mr. Jacobs expressly disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interest therein.
F2: By the Jeremy Brent Jacobs GST Non-Exempt u/a/d 04/26/2011 and Scott Douglas Jacobs GST Non-Exempt Trust u/a/d 04/26/2011.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AMSURG CORP
Report date December 01, 2016 · Filed December 01, 2016
Section 16 reporting ended · disclosed 2016-12-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2016-12-01 transaction · row 1
1 source rowRow 1 · 2016-12-01 · Disposition to issuer · Disposed 10,331 · Balance 0 F1: Disposition pursuant to the terms of the Agreement and Plan of Merger, dated as of June 15, 2016, by and among Envision Healthcare Holdings,Inc., New Amethyst Corp. and AmSurg Corp. (the "Merger Agreement"), exempt under Rule 16b-3. F2: Pursuant to the terms of the Merger Agreement, at the Merger 1 Effective Time (as defined in the Merger Agreement), each share of common stock held by the reporting person immediately prior to the Merger 1 Effective Time was assumed by New Amethyst and converted into a New Amethyst share of common stock having the same terms and conditions, taking into account any changes thereto by reason of the Mergers (as defined in the Merger Agreement). |
Filing footnotes · ownership attribution and instrument terms
F1: Disposition pursuant to the terms of the Agreement and Plan of Merger, dated as of June 15, 2016, by and among Envision Healthcare Holdings,Inc., New Amethyst Corp. and AmSurg Corp. (the "Merger Agreement"), exempt under Rule 16b-3.
F2: Pursuant to the terms of the Merger Agreement, at the Merger 1 Effective Time (as defined in the Merger Agreement), each share of common stock held by the reporting person immediately prior to the Merger 1 Effective Time was assumed by New Amethyst and converted into a New Amethyst share of common stock having the same terms and conditions, taking into account any changes thereto by reason of the Mergers (as defined in the Merger Agreement).
CUMBERLAND PHARMACEUTICALS INC
Report date January 14, 2023 · Filed March 21, 2023
Section 16 reporting ended · disclosed 2023-03-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 98,415 |
Reported balance
After 2023-01-14 transaction · row 1
1 source rowRow 1 · 2023-01-14 · Other · Disposed 5,000 · Balance 98,415 F1: Mr. Jacobs passed away January 14, 2023. All unvested equity awards forfeited upon death. |
Filing footnotes · ownership attribution and instrument terms
F1: Mr. Jacobs passed away January 14, 2023. All unvested equity awards forfeited upon death.
Envision Healthcare Corp
Report date October 11, 2018 · Filed October 15, 2018
Section 16 reporting ended · disclosed 2018-10-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-10-11 transaction · row 1
1 source rowRow 1 · 2018-10-11 · Disposition to issuer · Disposed 17,472 · Balance 0 F1: At the Effective Time, each share of common stock, par value $0.01 per share, of the Company ("Company Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Merger Agreement) was cancelled and converted into the right to receive $46.00 in cash, (the "Merger Consideration") without interest and subject to applicable withholding taxes. F2: Includes 4,017 restricted stock unit awards ("Company RSUs"). At the Effective Time, each Company RSU that was outstanding as of immediately prior to the Effective Time was converted into the right to receive an amount in cash equal to the sum of (i) the product of (A) the total number of shares of Company Common Stock subject to such Company RSU immediately prior to the Effective Time and (B) the Merger Consideration and (ii) any accrued but unpaid dividend equivalents with respect to such Company RSU. |
Filing footnotes · ownership attribution and instrument terms
F1: At the Effective Time, each share of common stock, par value $0.01 per share, of the Company ("Company Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Merger Agreement) was cancelled and converted into the right to receive $46.00 in cash, (the "Merger Consideration") without interest and subject to applicable withholding taxes.
F2: Includes 4,017 restricted stock unit awards ("Company RSUs"). At the Effective Time, each Company RSU that was outstanding as of immediately prior to the Effective Time was converted into the right to receive an amount in cash equal to the sum of (i) the product of (A) the total number of shares of Company Common Stock subject to such Company RSU immediately prior to the Effective Time and (B) the Merger Consideration and (ii) any accrued but unpaid dividend equivalents with respect to such Company RSU.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 14, 2023 Filed Mar 21, 2023 21:28 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | OtherCommon Stock | 5,000 | $2.75 | $13,750.00 |
DisclosureSEC source: 0001209191-23-020351 · doc4.xml · nonDerivative · entry 1 JACOBS JOEY A · CIK 0001243878 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,415 F1 · shares: Mr. Jacobs passed away January 14, 2023. All unvested equity awards forfeited upon death. Read SEC document |
| March 16, 2022 Filed Apr 29, 2022 17:05 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 5,000 | $2.59 | $12,950.00 |
DisclosureSEC source: 0001209191-22-026144 · doc4.xml · nonDerivative · entry 1 JACOBS JOEY A · CIK 0001243878 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,415 F1 · shares: Restricted stock award will vest 100% on March 16, 2023. Read SEC document |
| March 17, 2021 Filed Jun 11, 2021 21:20 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 5,000 | $3.22 | $16,100.00 |
DisclosureSEC source: 0001209191-21-039934 · doc4.xml · nonDerivative · entry 1 JACOBS JOEY A · CIK 0001243878 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,415 F1 · shares: Restricted stock award will vest 100% on March 17, 2022. Read SEC document |
| March 23, 2020 Filed Apr 17, 2020 21:22 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 5,000 | $3.56 | $17,800.00 |
DisclosureSEC source: 0001209191-20-024892 · doc4.xml · nonDerivative · entry 1 JACOBS JOEY A · CIK 0001243878 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,415 F1 · shares: Restricted stock award will vest 100% on March 23, 2021. Read SEC document |
| May 23, 2019 Filed May 31, 2019 21:12 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 850 | $6.44 | $5,474.00 |
DisclosureSEC source: 0001209191-19-033695 · doc4.xml · nonDerivative · entry 10 JACOBS JOEY A · CIK 0001243878 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,415 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| May 22, 2019 Filed May 31, 2019 21:12 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 850 | $6.49 | $5,516.50 |
DisclosureSEC source: 0001209191-19-033695 · doc4.xml · nonDerivative · entry 9 JACOBS JOEY A · CIK 0001243878 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,565 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| May 21, 2019 Filed May 31, 2019 21:12 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 850 | $6.49 | $5,516.50 |
DisclosureSEC source: 0001209191-19-033695 · doc4.xml · nonDerivative · entry 8 JACOBS JOEY A · CIK 0001243878 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,715 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| May 20, 2019 Filed May 31, 2019 21:12 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 850 | $6.89 | $5,856.50 |
DisclosureSEC source: 0001209191-19-033695 · doc4.xml · nonDerivative · entry 7 JACOBS JOEY A · CIK 0001243878 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,865 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| May 17, 2019 Filed May 31, 2019 21:12 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 794 | $6.20 | $4,922.80 |
DisclosureSEC source: 0001209191-19-033695 · doc4.xml · nonDerivative · entry 6 JACOBS JOEY A · CIK 0001243878 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,015 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| May 16, 2019 Filed May 31, 2019 21:12 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 301 | $5.99 | $1,802.99 |
DisclosureSEC source: 0001209191-19-033695 · doc4.xml · nonDerivative · entry 5 JACOBS JOEY A · CIK 0001243878 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,221 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| May 15, 2019 Filed May 31, 2019 21:12 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 677 | $6.00 | $4,062.00 |
DisclosureSEC source: 0001209191-19-033695 · doc4.xml · nonDerivative · entry 4 JACOBS JOEY A · CIK 0001243878 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,920 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| May 14, 2019 Filed May 31, 2019 21:12 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 66 | $5.48 | $361.68 |
DisclosureSEC source: 0001209191-19-033695 · doc4.xml · nonDerivative · entry 3 JACOBS JOEY A · CIK 0001243878 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,243 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| May 13, 2019 Filed May 31, 2019 21:12 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 526 | $5.67 | $2,982.42 |
DisclosureSEC source: 0001209191-19-033695 · doc4.xml · nonDerivative · entry 2 JACOBS JOEY A · CIK 0001243878 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,177 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| May 10, 2019 Filed May 31, 2019 21:12 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 931 | $5.92 | $5,511.52 |
DisclosureSEC source: 0001209191-19-033695 · doc4.xml · nonDerivative · entry 1 JACOBS JOEY A · CIK 0001243878 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,651 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| May 08, 2019 Filed May 10, 2019 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 933 | $6.26 | $5,840.58 |
DisclosureSEC source: 0001209191-19-029024 · doc4.xml · nonDerivative · entry 8 JACOBS JOEY A · CIK 0001243878 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,720 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| May 07, 2019 Filed May 10, 2019 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 361 | $5.83 | $2,104.63 |
DisclosureSEC source: 0001209191-19-029024 · doc4.xml · nonDerivative · entry 7 JACOBS JOEY A · CIK 0001243878 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,787 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| May 06, 2019 Filed May 10, 2019 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 686 | $6.16 | $4,225.76 |
DisclosureSEC source: 0001209191-19-029024 · doc4.xml · nonDerivative · entry 6 JACOBS JOEY A · CIK 0001243878 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,426 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| May 02, 2019 Filed May 10, 2019 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 748 | $5.38 | $4,024.24 |
DisclosureSEC source: 0001209191-19-029024 · doc4.xml · nonDerivative · entry 5 JACOBS JOEY A · CIK 0001243878 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,740 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| May 01, 2019 Filed May 10, 2019 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 441 | $5.51 | $2,429.91 |
DisclosureSEC source: 0001209191-19-029024 · doc4.xml · nonDerivative · entry 4 JACOBS JOEY A · CIK 0001243878 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,992 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| April 30, 2019 Filed May 10, 2019 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 98 | $5.74 | $562.52 |
DisclosureSEC source: 0001209191-19-029024 · doc4.xml · nonDerivative · entry 3 JACOBS JOEY A · CIK 0001243878 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,551 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| April 29, 2019 Filed May 10, 2019 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 343 | $5.81 | $1,992.83 |
DisclosureSEC source: 0001209191-19-029024 · doc4.xml · nonDerivative · entry 2 JACOBS JOEY A · CIK 0001243878 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,453 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| April 26, 2019 Filed May 10, 2019 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 236 | $5.92 | $1,397.12 |
DisclosureSEC source: 0001209191-19-029024 · doc4.xml · nonDerivative · entry 1 JACOBS JOEY A · CIK 0001243878 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,110 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| April 25, 2019 Filed Apr 26, 2019 21:30 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 385 | $5.94 | $2,286.90 |
DisclosureSEC source: 0001209191-19-026277 · doc4.xml · nonDerivative · entry 10 JACOBS JOEY A · CIK 0001243878 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,874 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| April 24, 2019 Filed Apr 26, 2019 21:30 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 86 | $5.97 | $513.42 |
DisclosureSEC source: 0001209191-19-026277 · doc4.xml · nonDerivative · entry 9 JACOBS JOEY A · CIK 0001243878 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,489 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| April 23, 2019 Filed Apr 26, 2019 21:30 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommonStock | 392 | $5.98 | $2,344.16 |
DisclosureSEC source: 0001209191-19-026277 · doc4.xml · nonDerivative · entry 8 JACOBS JOEY A · CIK 0001243878 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,403 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| April 22, 2019 Filed Apr 26, 2019 21:30 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 49 | $6.12 | $299.88 |
DisclosureSEC source: 0001209191-19-026277 · doc4.xml · nonDerivative · entry 7 JACOBS JOEY A · CIK 0001243878 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,011 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| April 17, 2019 Filed Apr 26, 2019 21:30 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 484 | $6.09 | $2,947.56 |
DisclosureSEC source: 0001209191-19-026277 · doc4.xml · nonDerivative · entry 6 JACOBS JOEY A · CIK 0001243878 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,962 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| April 16, 2019 Filed Apr 26, 2019 21:30 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 49 | $6.22 | $304.78 |
DisclosureSEC source: 0001209191-19-026277 · doc4.xml · nonDerivative · entry 5 JACOBS JOEY A · CIK 0001243878 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,478 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| April 15, 2019 Filed Apr 26, 2019 21:30 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 784 | $6.15 | $4,821.60 |
DisclosureSEC source: 0001209191-19-026277 · doc4.xml · nonDerivative · entry 4 JACOBS JOEY A · CIK 0001243878 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,429 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| April 12, 2019 Filed Apr 26, 2019 21:30 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 490 | $6.26 | $3,067.40 |
DisclosureSEC source: 0001209191-19-026277 · doc4.xml · nonDerivative · entry 3 JACOBS JOEY A · CIK 0001243878 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,645 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| April 11, 2019 Filed Apr 26, 2019 21:30 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 139 | $6.17 | $857.63 |
DisclosureSEC source: 0001209191-19-026277 · doc4.xml · nonDerivative · entry 2 JACOBS JOEY A · CIK 0001243878 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,155 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| April 10, 2019 Filed Apr 26, 2019 21:30 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 850 | $6.29 | $5,346.50 |
DisclosureSEC source: 0001209191-19-026277 · doc4.xml · nonDerivative · entry 1 JACOBS JOEY A · CIK 0001243878 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,016 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| April 09, 2019 Filed Apr 12, 2019 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 850 | $6.31 | $5,363.50 |
DisclosureSEC source: 0001209191-19-024498 · doc4.xml · nonDerivative · entry 7 JACOBS JOEY A · CIK 0001243878 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,166 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| April 08, 2019 Filed Apr 12, 2019 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 850 | $5.89 | $5,006.50 |
DisclosureSEC source: 0001209191-19-024498 · doc4.xml · nonDerivative · entry 6 JACOBS JOEY A · CIK 0001243878 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,316 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| April 05, 2019 Filed Apr 12, 2019 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 183 | $6.32 | $1,156.56 |
DisclosureSEC source: 0001209191-19-024498 · doc4.xml · nonDerivative · entry 5 JACOBS JOEY A · CIK 0001243878 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,466 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| April 04, 2019 Filed Apr 12, 2019 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 241 | $6.19 | $1,491.79 |
DisclosureSEC source: 0001209191-19-024498 · doc4.xml · nonDerivative · entry 4 JACOBS JOEY A · CIK 0001243878 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,283 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| April 03, 2019 Filed Apr 12, 2019 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 80 | $6.00 | $480.00 |
DisclosureSEC source: 0001209191-19-024498 · doc4.xml · nonDerivative · entry 3 JACOBS JOEY A · CIK 0001243878 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,042 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| April 02, 2019 Filed Apr 12, 2019 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 580 | $6.12 | $3,549.60 |
DisclosureSEC source: 0001209191-19-024498 · doc4.xml · nonDerivative · entry 2 JACOBS JOEY A · CIK 0001243878 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,962 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| April 01, 2019 Filed Apr 12, 2019 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 382 | $5.99 | $2,288.18 |
DisclosureSEC source: 0001209191-19-024498 · doc4.xml · nonDerivative · entry 1 JACOBS JOEY A · CIK 0001243878 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,382 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| March 22, 2019 Filed Mar 22, 2019 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 5,000 | $5.98 | $29,900.00 |
DisclosureSEC source: 0001209191-19-021034 · doc4.xml · nonDerivative · entry 1 JACOBS JOEY A · CIK 0001243878 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,000 F1 · shares: Restricted stock award will vest 100% on March 18, 2020. Read SEC document |
| March 07, 2019 Filed Mar 8, 2019 17:01 UTC | Acadia Healthcare Company, Inc. ACHC · Entity 4312 | Exercise / conversionEmployee Stock Options (right to buy) · Derivative | 18,315 | $0.00 Strike: $15.96 | $0.00 |
DisclosureSEC source: 0000899243-19-006933 · doc4.xml · derivative · entry 3 JACOBS JOEY A · CIK 0001243878 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,315 shares Expires 2019-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 07, 2019 Filed Mar 8, 2019 17:01 UTC | Acadia Healthcare Company, Inc. ACHC · Entity 4312 | Exercise / conversionCommon Stock | 18,315 | $15.96 | $292,307.40 |
DisclosureSEC source: 0000899243-19-006933 · doc4.xml · nonDerivative · entry 1 JACOBS JOEY A · CIK 0001243878 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,388 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2018 Filed Feb 13, 2019 17:04 UTC | Acadia Healthcare Company, Inc. ACHC · Entity 4312 | Tax withholdingCommon Stock | 36,126 | $28.93 | $1,045,125.18 |
DisclosureSEC source: 0000899243-19-003449 · doc5.xml · nonDerivative · entry 1 JACOBS JOEY A · CIK 0001243878 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,073 Read SEC document |
| October 11, 2018 Filed Oct 15, 2018 12:52 UTC | Envision Healthcare Corp EVHC · Entity 162981 | Disposition to issuerCommon Stock | 17,472 | $46.00 | $803,712.00 |
DisclosureSEC source: 0001678531-18-000149 · wf-form4_153962235290865.xml · nonDerivative · entry 1 JACOBS JOEY A · CIK 0001243878 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: At the Effective Time, each share of common stock, par value $0.01 per share, of the Company ("Company Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Merger Agreement) was cancelled and converted into the right to receive $46.00 in cash, (the "Merger Consideration") without interest and subject to applicable withholding taxes. F2 · shares: Includes 4,017 restricted stock unit awards ("Company RSUs"). At the Effective Time, each Company RSU that was outstanding as of immediately prior to the Effective Time was converted into the right to receive an amount in cash equal to the sum of (i) the product of (A) the total number of shares of Company Common Stock subject to such Company RSU immediately prior to the Effective Time and (B) the Merger Consideration and (ii) any accrued but unpaid dividend equivalents with respect to such Company RSU. F1 · price: At the Effective Time, each share of common stock, par value $0.01 per share, of the Company ("Company Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Merger Agreement) was cancelled and converted into the right to receive $46.00 in cash, (the "Merger Consideration") without interest and subject to applicable withholding taxes. Read SEC document |
| May 25, 2018 Filed May 29, 2018 18:16 UTC | Envision Healthcare Corp EVHC · Entity 162981 | GrantCommon Stock | 4,017 | $43.57 | $175,020.69 |
DisclosureSEC source: 0001678531-18-000081 · wf-form4_152763211453699.xml · nonDerivative · entry 1 JACOBS JOEY A · CIK 0001243878 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,472 F1 · kind: Represents the annual restricted stock unit award granted to non-employee directors for service on the Company's board of directors (the "Board"). The restricted stock units vest on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the Company's next annual shareholders meeting, in each case subject to continued service on the Board, and will be settled upon vesting. Read SEC document |
| March 23, 2018 Filed Mar 23, 2018 21:41 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 5,000 | $6.70 | $33,500.00 |
DisclosureSEC source: 0001209191-18-021465 · doc4.xml · nonDerivative · entry 1 JACOBS JOEY A · CIK 0001243878 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,000 F1 · shares: Restricted stock award will vest 100% on March 20, 2019. Read SEC document |
| March 02, 2018 Filed Mar 7, 2018 20:24 UTC | Acadia Healthcare Company, Inc. ACHC · Entity 4312 | GrantCommon Stock | 42,747 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-006751 · doc4.xml · nonDerivative · entry 1 JACOBS JOEY A · CIK 0001243878 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,199 F1 · shares: Shares will vest over a 4-year period in equal yearly installments beginning March 2, 2019. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 17:03 UTC | Acadia Healthcare Company, Inc. ACHC · Entity 4312 | GrantCommon Stock | 26,335 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-006150 · doc4.xml · nonDerivative · entry 2 JACOBS JOEY A · CIK 0001243878 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241,452 F2 · shares: Shares received upon vesting of performance vesting restricted stock units awarded on March 29, 2017. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 17:03 UTC | Acadia Healthcare Company, Inc. ACHC · Entity 4312 | GrantCommon Stock | 13,621 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-006150 · doc4.xml · nonDerivative · entry 1 JACOBS JOEY A · CIK 0001243878 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,117 F1 · shares: Shares received upon vesting of performance vesting restricted stock units awarded on February 24, 2015. Read SEC document |
| August 22, 2017 Filed Aug 22, 2017 18:13 UTC | Acadia Healthcare Company, Inc. ACHC · Entity 4312 | SaleCommon Stock | 300,000 | $50.69 | $15,207,000.00 |
DisclosureSEC source: 0000899243-17-020878 · doc4.xml · nonDerivative · entry 2 JACOBS JOEY A · CIK 0001243878 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 267,649 F1 · balance_after: Mr. Jacobs expressly disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interest therein. F2 · ownership.nature: By the Jeremy Brent Jacobs GST Non-Exempt u/a/d 04/26/2011 and Scott Douglas Jacobs GST Non-Exempt Trust u/a/d 04/26/2011. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.